



NIH-AACR Cancer, Autoimmunity, and Immunology Conference

March 23-24, 2020

Julie R. Brahmer, MD, Codirector, Upper Aerodigestive Clinical Research Program, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Elad Sharon, MD, MPH, Senior Investigator, National Cancer Institute

Connie Sommers, PhD, Program Director, National Cancer Institute

Howard Young, PhD, Senior Investigator, National Cancer Institute

Ravi Madan, MD, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute

Katarzyna (Kasia) Bourcier, PhD, Program Director, National Cancer Institute

Marie Mancini, PhD, Program Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Annette Rothermel, PhD, Section Chief, National Institute of Allergy and Infectious Diseases

Lisa Spain, PhD, Program Director, National Institute of Diabetes and Digestive and Kidney Diseases

AGENDA: MARCH 23, 2020

INTRODUCTION

9:00 AM Welcome and opening remarks
Hugh Auchincloss, MD, National Institute of Allergy and Infectious Diseases

KEYNOTE ADDRESS

9:15 AM Understanding the immunopathogenesis of irAEs and the prospects for targeted therapy
Leonard H. Calabrese, DO, FACR, Cleveland Clinic

SESSION I: RHEUMATIC TOXICITIES

SESSION MODERATOR: LEONARD H. CALABRESE, DO, FACR

9:45 AM Rheumatologic immune-related adverse events: Not our classic autoimmune diseases
Laura C. Cappelli, MD, MHS, MS, Johns Hopkins University

10:00 AM Rheumatic toxicities associated with immune checkpoint inhibitors: The severity of myositis
Yves Allenbach, MD, PhD, Sorbonne Université

10:15 AM Seeing is believing: Imaging modalities in rheumatologic immune-related adverse events
Sarthak Gupta, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases

10:30 AM PANEL DISCUSSION

11:00 AM BREAK

SESSION II: INFECTIOUS DISEASES

SESSION MODERATOR: VIRGINIA SHEIKH, MD, MHS

11:30 AM Effects of immune checkpoint blockade on HIV latency
Rafick-Pierre Sékaly, PhD, Case Western Reserve University

11:45 AM Preclinical TB work in Macaques
Dan Barber, PhD, National Institute of Allergy and Infectious Diseases

12:00 PM **PD-1 inhibitors for the treatment of progressive multifocal leukoencephalopathy**
Irene Cortese, MD, National Institute of Neurological Disorders and Stroke

12:15 PM **PANEL DISCUSSION**

12:45 PM **LUNCH BREAK**

SESSION III: ROLE OF THE MICROBIOME
SESSION MODERATOR: GIORGIO TRINCHIERI, MD

2:00 PM **The role of the gut-tumor axis in tumorigenesis**
Florenca McAllister, MD, MD Anderson Cancer Center

2:15 PM **Treatment of refractory melanoma patients with fecal microbiota transplants and immunotherapy**
Gal Markel, MD, PhD, Sheba Medical Center

2:30 PM **Manipulating the microbiome to treat inflammatory cardiomyopathy**
Burkhard Ludewig, DVM, Kantonsspital St. Gallen

2:45 PM **PANEL DISCUSSION**

SESSION IV: PREDICTIVE BIOMARKERS
SESSION MODERATOR: DOUGLAS B. JOHNSON, MD

3:15 PM **Characterizing toxicities of immune checkpoint inhibitors**
Douglas B. Johnson, MD, Vanderbilt-Ingram Cancer Center

3:30 PM **Defining the features of T cell responses to tumor and self-antigens as predictors of response to checkpoint inhibitor therapy**
Jane Buckner, MD, Benaroya Research Institute

3:45 PM **Statistical considerations for evaluating biomarkers for irAEs**
Lisa Meier McShane, PhD, National Cancer Institute

4:00 PM **PANEL DISCUSSION**

4:30 PM **ADJOURN DAY 1**





NIH-AACR Cancer, Autoimmunity, and Immunology Conference

AGENDA: MARCH 24, 2020

INTRODUCTION

9:00 AM Welcome
Norman E. "Ned" Sharpless, MD, National Cancer Institute

KEYNOTE ADDRESS

9:10 AM Immune checkpoint blockade in cancer therapy: At the interface between anti-tumor and anti-self immunity
Suzanne L. Topalian, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

9:45 AM BREAK

SESSION V: IRAES RESULTING FROM COMBINATION THERAPIES

SESSION MODERATOR: JULIE BRAHMER, MD

10:05 AM Differentiation of dermatologic irAEs for patients on combination therapies: A consultant's perspective
Mario E. Lacouture, MD, Memorial Sloan-Kettering Cancer Center

10:20 AM Differentiating between irAEs and other AEs in combination therapies
Lilian L. Siu, MD, Princess Margaret Cancer Centre

10:35 AM irAEs from RT + ICI
Silvia Formenti, MD, Weill Cornell Medicine

10:50 AM PANEL DISCUSSION

11:30 AM LUNCH BREAK

SESSION VI: NONTRADITIONAL NONCLINICAL MODELS

SESSION MODERATOR: KRISTINA HOWARD, DVM, PHD

12:45 PM Wild mouse microbiota in preclinical research
Barbara Rehermann, MD, National Institute of Diabetes and Digestive and Kidney Diseases

1:00 PM Programmable bacteria for cancer
Tal Danino, PhD, Columbia University

1:15 PM A better HCC model for immunotherapy, in woodchucks?
Minhyung Kim, MD, Roswell Park Comprehensive Cancer Center

1:30 PM CANINE: A comparative genomics, oncology, and immunotherapy consortium
Melissa Renee Chambers, DVM, MD, University of Alabama at Birmingham

1:45 PM PANEL DISCUSSION



SESSION VII: MULTIDISCIPLINARY TREATMENT MODELS

SESSION MODERATOR: NICOLE R. LEBOEUF, MD, MPH

- 2:15 PM** **Severe Immunotherapy Complications (SIC) Service: A model integrating clinical care and clinical-translational research**
Kerry Reynolds, MD, Massachusetts General Hospital Cancer Center, and
Alexandra-Chloé Villani, PhD, Massachusetts General Hospital, Harvard Medical School, Broad Institute
- 2:35 PM** **A multidisciplinary immune-related toxicity team and prospective clinical trials for irAEs**
Jarushka Naidoo, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- 2:50 PM** **Management of immune checkpoint inhibitor-related GI toxicity**
Yinghong “Mimi” Wang, MD, PhD, MS, MD Anderson Cancer Center
- 3:05 PM** **Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events**
David Kozono, MD, PhD, Dana-Farber Cancer Institute
- 3:20 PM** **PANEL DISCUSSION**
- 4:00 PM** **WRAP-UP AND ADJOURN**

